Literature DB >> 1373957

Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.

R Leo1, M Boeker, D Peest, R Hein, R Bartl, J E Gessner, J Selbach, G Wacker, H Deicher.   

Abstract

Plasma cells obtained from bone marrow samples of 45 patients with MM, eight patients with MGUS, eight patients with Waldenström's macroglobulinaemia (WM), one patient with immunocytoma, and 12 controls were characterized by immunophenotyping, estimation of DNA content, and labeling index, as well as by morphological analysis. Plasma cells from 37/45 myeloma and 5/8 MGUS patients expressed CD38 and CD56 (N-CAM) on their surface but were negative for other NK cell-associated antigens such as CD16 (Fc gamma RIII) or CD2. All tumor cells of less-differentiated cell type (WM, immunocytoma) and normal polyclonal plasma cells were negative for CD56. CD56-specific mRNA was demonstrated in myeloma cells by northern blot analysis. Another adhesion molecule, ICAM-1 (CD54), was found on plasma cells from all patients and controls examined. Coexpression of CD19 (1/45), CD20 (9/45), or CD33 (3/45) was rare and CD10 with CD14 was expressed by a small tumor cell subpopulation of only one myeloma patient. The individual pattern of surface marker expression was not associated with a special-type myeloma protein isotype, stage or status of disease, LI or histological classification; however, a correlation between CD56 expression or histological classification and DNA content of the tumor cells was found.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373957     DOI: 10.1007/bf01697400

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  39 in total

1.  Prognostic implications of tumor cell DNA and RNA content in multiple myeloma.

Authors:  B Barlogie; R Alexanian; D Dixon; L Smith; L Smallwood; K Delasalle
Journal:  Blood       Date:  1985-08       Impact factor: 22.113

2.  Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features.

Authors:  T M Grogan; B G Durie; C Lomen; C Spier; D P Wirt; R Nagle; G S Wilson; L Richter; E Vela; V Maxey
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

3.  An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens.

Authors:  N Jackson; N R Ling; J Ball; E Bromidge; P D Nathan; I M Franklin
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

4.  Idiotype-bearing lymphoid cells in plasma cell neoplasia.

Authors:  H Mellstedt; G Holm; D Pettersson; D Peest
Journal:  Clin Haematol       Date:  1982-02

5.  Studies on the origin of the precursor cells in multiple myeloma, Waldenström's macroglobulinaemia and benign monoclonal gammopathy. I. Cytoplasmic isotype and idiotype distribution in peripheral blood and bone marrow.

Authors:  B Van Camp; P Reynaert; L Broodtaerts
Journal:  Clin Exp Immunol       Date:  1981-04       Impact factor: 4.330

6.  Cellular DNA content as a marker of human multiple myeloma.

Authors:  J Latreille; B Barlogie; G Dosik; D A Johnston; B Drewinko; R Alexanian
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

7.  Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development.

Authors:  M R Loken; V O Shah; K L Dattilio; C I Civin
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

8.  Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.

Authors:  J F San Miguel; M González; A Gascón; M J Moro; J M Hernández; F Ortega; R Jimenez; L Guerras; M Romero; F Casanova
Journal:  Br J Haematol       Date:  1991-02       Impact factor: 6.998

9.  CALLA-positive myeloma: an aggressive subtype with poor survival.

Authors:  B G Durie; T M Grogan
Journal:  Blood       Date:  1985-07       Impact factor: 22.113

10.  Myelomonocytic antigen positive multiple myeloma.

Authors:  T M Grogan; B G Durie; C M Spier; L Richter; E Vela
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

View more
  22 in total

1.  CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.

Authors:  M Zandecki; T Facon; F Bernardi; V Izydorczyk; L Dupond; M François; R Reade; T Iaru; F Bauters; A Cosson
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

2.  Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.

Authors:  Yumi Nakayama; Jolanta Kosek; Lori Capone; Eun Mi Hur; Peter H Schafer; Garth E Ringheim
Journal:  J Immunol       Date:  2017-08-28       Impact factor: 5.422

3.  Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.

Authors:  H Diem; A Fateh-Moghadam; R Lamerz
Journal:  Clin Investig       Date:  1993-11

4.  The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.

Authors:  Subhashis Sarkar; Sachin K S Chauhan; John Daly; Alessandro Natoni; Heather Fairfield; Robert Henderson; Emma Nolan; Dawn Swan; Jinsong Hu; Michaela R Reagan; Michael O'Dwyer
Journal:  Cancer Immunol Immunother       Date:  2020-01-09       Impact factor: 6.968

Review 5.  Immunophenotyping in multiple myeloma and related plasma cell disorders.

Authors:  Shaji Kumar; Teresa Kimlinger; William Morice
Journal:  Best Pract Res Clin Haematol       Date:  2010-09       Impact factor: 3.020

Review 6.  The development of potential antibody-based therapies for myeloma.

Authors:  Daniel W Sherbenou; Christopher R Behrens; Yang Su; Jeffrey L Wolf; Thomas G Martin; Bin Liu
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 7.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

Review 8.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

9.  Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Authors:  M Ocqueteau; A Orfao; J Almeida; J Bladé; M González; R García-Sanz; C López-Berges; M J Moro; J Hernández; L Escribano; D Caballero; M Rozman; J F San Miguel
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).

Authors:  D M Menke; H P Horny; H Griesser; E J Atkinson; E Kaiserling; R A Kyle
Journal:  J Clin Pathol       Date:  1998-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.